PE20050924A1 - Compuestos de tiazolidinonas como inhibidores de quinasa tipo polo (plk) - Google Patents
Compuestos de tiazolidinonas como inhibidores de quinasa tipo polo (plk)Info
- Publication number
- PE20050924A1 PE20050924A1 PE2004001044A PE2004001044A PE20050924A1 PE 20050924 A1 PE20050924 A1 PE 20050924A1 PE 2004001044 A PE2004001044 A PE 2004001044A PE 2004001044 A PE2004001044 A PE 2004001044A PE 20050924 A1 PE20050924 A1 PE 20050924A1
- Authority
- PE
- Peru
- Prior art keywords
- alkyl
- ethyl
- plk
- polo
- iliden
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/34—Oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Biotechnology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychology (AREA)
- AIDS & HIV (AREA)
- Vascular Medicine (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pulmonology (AREA)
- Toxicology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Abstract
SE REFIERE A UN COMPUESTO DE FORMULA I DONDE Q ES ARILO O HETEROARILO; A Y B SON CADA UNO H, HALOGENO, HIDROXI, AMINO, ALQUILO C1-C3, ENTRE OTROS; X ES -NH-, -NR5-; R1 ES ALQUILO C1-C4, ALILO O PROPARGILO OPCIONALMENTE SUSTITUIDOS; ENTRE OTROS; R2 ES H, ALQUILO C1-C6, ALCOXI C1-C6, ALQUENILO C1-C6, ENTRE OTROS; R5 ALQUILO C1-C6, ALQUENILO C3-C6, ALQUINILO C3-C6 OPCIONALMENTE SUSTITUIDO, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: ESTER ETILICO DEL ACIDO (E O Z)-CIANO-(3-ETIL-5-(E/Z)-{[4-(2-MORFOLIN-4-IL-ETANSULFONILAMINO)-FENILAMINO]-METILEN}-4-OXO-TIAZOLIDIN-2-ILIDEN)-ACETICO; ESTER ALILICO DEL ACIDO (E O Z)-CIANO-(3-ETIL-5-(E/Z)-({4-[3-(4-METIL-PIPERAZIN-1-IL)-PROPIONILAMINO]-FENILAMINO}-METILEN}-4-OXO-TIAZOLIDIN-2-ILIDEN)-ACETICO; ESTER ETILICO DEL ACIDO (E O Z)-CIANO-[3-ETIL-4-OXO-5-(E/Z)-(M-TOLILAMINO-METILEN)-TIAZOLIDIN-2-ILIDEN]-ACETICO, ENTRE OTROS. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA Y A UN METODO DE PREPARACION. DICHOS COMPUESTOS SON INHIBIDORES DE LA QUINASA TIPO POLO (PLK) UTILES EN EL TRATAMIENTO DE CANCER, ENFERMEDADES AUTOINMUNES, CARDIOVASCULARES, INFECCIOSAS, ENTRE OTRAS
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10351744A DE10351744A1 (de) | 2003-10-31 | 2003-10-31 | Thiazolidinone, deren Herstellung und Verwendung als Arzneimittel |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20050924A1 true PE20050924A1 (es) | 2005-11-25 |
Family
ID=34530142
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2004001044A PE20050924A1 (es) | 2003-10-31 | 2004-10-29 | Compuestos de tiazolidinonas como inhibidores de quinasa tipo polo (plk) |
Country Status (20)
Country | Link |
---|---|
US (1) | US20070037862A1 (es) |
EP (1) | EP1678153A1 (es) |
JP (1) | JP2007509892A (es) |
KR (1) | KR20060098374A (es) |
CN (1) | CN1902185A (es) |
AR (1) | AR046347A1 (es) |
AU (1) | AU2004285682A1 (es) |
BR (1) | BRPI0416005A (es) |
CA (1) | CA2544267A1 (es) |
CR (1) | CR8385A (es) |
DE (1) | DE10351744A1 (es) |
EA (1) | EA200600833A1 (es) |
EC (1) | ECSP066588A (es) |
IL (1) | IL175245A0 (es) |
NO (1) | NO20062453L (es) |
PE (1) | PE20050924A1 (es) |
RS (1) | RS20060294A (es) |
TW (1) | TW200530230A (es) |
WO (1) | WO2005042505A1 (es) |
ZA (1) | ZA200604432B (es) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BRPI0517834A (pt) | 2004-11-12 | 2008-10-21 | Bayer Schering Pharma Ag | vìrus da doença de newcastle recombinante |
KR20070092740A (ko) * | 2004-12-15 | 2007-09-13 | 바이엘 쉐링 파마 악티엔게젤샤프트 | 메타-치환된 티아졸리디논, 이의 제조 방법 및의약으로서의 용도 |
DE102004061503A1 (de) * | 2004-12-15 | 2006-06-29 | Schering Ag | Metasubstituierte Thiazolidinone, deren Herstellung und Verwendung als Arzneimittel |
DE102005005395A1 (de) | 2005-02-03 | 2006-08-10 | Schering Aktiengesellschaft | Thiazolidinone, deren Herstellung und Verwendung als Arzneimittel |
DE102005055892A1 (de) * | 2005-11-22 | 2007-05-24 | Henkel Kgaa | Neue Kupplerkomponenten |
EP1989330A4 (en) * | 2006-01-31 | 2009-10-21 | Elan Pharm Inc | ALPHA-SYNUCLEINE KINASE |
US7504513B2 (en) | 2006-02-27 | 2009-03-17 | Hoffman-La Roche Inc. | Thiazolyl-benzimidazoles |
FR2904317A1 (fr) * | 2006-07-27 | 2008-02-01 | Inst Nat Sante Rech Med | Analogues d'halogenobenzamides marques a titre de radiopharmaceutiques |
EP2085390A1 (en) * | 2008-01-31 | 2009-08-05 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Labelled analogues of halobenzamides as multimodal radiopharmaceuticals and their precursors |
EP2247748A2 (en) * | 2008-02-13 | 2010-11-10 | Elan Pharma International Limited | Alpha-synuclein kinase |
EP2100894A1 (en) | 2008-03-12 | 2009-09-16 | 4Sc Ag | Pyridopyrimidines used as Plk1 (polo-like kinase) inhibitors |
EP2141163A1 (de) * | 2008-07-02 | 2010-01-06 | Bayer Schering Pharma AG | Substituierte Thiazolidinone, deren Herstellung und Verwendung als Arzneimittel |
JP2012512223A (ja) | 2008-12-18 | 2012-05-31 | エフ.ホフマン−ラ ロシュ アーゲー | チアゾリル−ベンズイミダゾール類 |
CN102584809B (zh) * | 2011-01-14 | 2014-12-24 | 湘北威尔曼制药股份有限公司 | 胺基噻唑烷酮化合物及其制备方法与在制备抗肿瘤药物中的应用 |
WO2014069434A1 (ja) * | 2012-10-30 | 2014-05-08 | カルナバイオサイエンス株式会社 | 新規チアゾリジノン誘導体 |
WO2018136635A1 (en) * | 2017-01-18 | 2018-07-26 | Coherus Biosciences, Inc. | Pparϒ agonist for the treatment of huntington's disease |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MXPA03008117A (es) * | 2001-03-07 | 2004-11-12 | Incyte San Diego Inc | Derivados heterociclicos para el tratamiento del cancer y otras enfermedades proliferativas. |
BR0309758A (pt) * | 2002-05-03 | 2005-02-15 | Schering Ag | Tiazolidinonas e seu uso como inibidortes de cinase semelhante a polo |
-
2003
- 2003-10-31 DE DE10351744A patent/DE10351744A1/de not_active Ceased
-
2004
- 2004-10-15 TW TW093131417A patent/TW200530230A/zh unknown
- 2004-10-26 EA EA200600833A patent/EA200600833A1/ru unknown
- 2004-10-26 RS YUP-2006/0294A patent/RS20060294A/sr unknown
- 2004-10-26 AU AU2004285682A patent/AU2004285682A1/en not_active Abandoned
- 2004-10-26 EP EP04791006A patent/EP1678153A1/de not_active Withdrawn
- 2004-10-26 CA CA002544267A patent/CA2544267A1/en not_active Abandoned
- 2004-10-26 CN CNA2004800392407A patent/CN1902185A/zh active Pending
- 2004-10-26 WO PCT/EP2004/012242 patent/WO2005042505A1/de active Application Filing
- 2004-10-26 BR BRPI0416005-3A patent/BRPI0416005A/pt not_active IP Right Cessation
- 2004-10-26 JP JP2006537202A patent/JP2007509892A/ja active Pending
- 2004-10-26 KR KR1020067008226A patent/KR20060098374A/ko not_active Application Discontinuation
- 2004-10-29 AR ARP040103953A patent/AR046347A1/es not_active Application Discontinuation
- 2004-10-29 PE PE2004001044A patent/PE20050924A1/es not_active Application Discontinuation
- 2004-11-01 US US10/978,225 patent/US20070037862A1/en not_active Abandoned
-
2006
- 2006-04-27 IL IL175245A patent/IL175245A0/en unknown
- 2006-05-05 CR CR8385A patent/CR8385A/es unknown
- 2006-05-29 EC EC2006006588A patent/ECSP066588A/es unknown
- 2006-05-30 NO NO20062453A patent/NO20062453L/no not_active Application Discontinuation
- 2006-05-30 ZA ZA200604432A patent/ZA200604432B/xx unknown
Also Published As
Publication number | Publication date |
---|---|
RS20060294A (en) | 2008-08-07 |
CR8385A (es) | 2006-10-04 |
DE10351744A1 (de) | 2005-06-16 |
BRPI0416005A (pt) | 2007-01-02 |
AR046347A1 (es) | 2005-12-07 |
WO2005042505A1 (de) | 2005-05-12 |
ZA200604432B (en) | 2009-09-30 |
IL175245A0 (en) | 2006-09-05 |
ECSP066588A (es) | 2006-10-17 |
TW200530230A (en) | 2005-09-16 |
NO20062453L (no) | 2006-07-28 |
CA2544267A1 (en) | 2005-05-12 |
CN1902185A (zh) | 2007-01-24 |
EA200600833A1 (ru) | 2007-02-27 |
JP2007509892A (ja) | 2007-04-19 |
AU2004285682A1 (en) | 2005-05-12 |
KR20060098374A (ko) | 2006-09-18 |
EP1678153A1 (de) | 2006-07-12 |
US20070037862A1 (en) | 2007-02-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20050924A1 (es) | Compuestos de tiazolidinonas como inhibidores de quinasa tipo polo (plk) | |
PE20060215A1 (es) | 4-fenilamino-quinazolin-6-il-amidas | |
PE20081059A1 (es) | Derivados de pirimidinas como inhibidores de la actividad de la tirosina quinasa de bruton (btk) | |
PE20110598A1 (es) | Inhibidores de las enzimas de proteina cinasa activadas por mitogeno p38 | |
PE20120355A1 (es) | DERIVADOS DE PIRAZOL COMO INHIBIDORES DE LA ENZIMA 11ßHSD1 | |
PE20070136A1 (es) | COMPUESTOS DERIVADOS DE N-(PIRIDIN-2-IL)-SULFONAMIDA COMO INHIBIDORES DE LA ENZIMA 11-beta-HIDROXIESTEROIDE DESHIDROGENASA HUMANA TIPO 1 | |
PE20061490A1 (es) | Derivados de ciclohexanosulfonilo como inhibidores del transportador de glicina glyt1 | |
PE20070550A1 (es) | Derivados de la 1-amino-ftalazina sustituida afines al receptor mch1 y su preparacion | |
PE20090773A1 (es) | Derivados de morfolina pirimidina | |
PE20090813A1 (es) | Inhibidores de la 11b-hidroxiesteroide-deshidrogenasa | |
PE20061198A1 (es) | Derivados de pirazol como inhibidores de cdk y gsk | |
PE20120690A1 (es) | Derivados de 5-fluoropirimidinona | |
PE20050872A1 (es) | Compuestos 5-fenil-tiazol-2-il-amida como inhibidores de la enzima fosfatidilinositol 3-cinasa | |
CO5700757A2 (es) | Derivados de (3-oxo-3,4-dihidro-quinoxalin-2-il-amino)-benzamida y compuesto relacionado, como inhibidores de glucogeno fosforilasa para el tratamiento de la diabetes y obesidad | |
PE20091376A1 (es) | Derivados de fenilamino como moduladores de beta-amiloide | |
PE20050948A1 (es) | Compuestos de carbamoil-amina como inhibidores de la dipeptidil peptidasa iv | |
PE20060777A1 (es) | Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas | |
TW200635585A (en) | Monocyclic substituted methanones | |
PE20081636A1 (es) | Inhibidores de antranilamida para aurora quinasa | |
PE20060748A1 (es) | Derivados de indolcarboxamida como inhibidores de quinasa ikk2 | |
PE20080404A1 (es) | Derivados bencil-amino-piperidina como inhibidores de cetp | |
PE20051170A1 (es) | DERIVADOS DE PIRROL COMO INHIBIDORES DEL FACTOR Xa | |
PE20080856A1 (es) | Inhibidores de metaloproteasas de matriz | |
PE20121352A1 (es) | Derivados de heteroarilo que contienen n como inhibidores de cinasa jak3 | |
PE20060589A1 (es) | FENILAMINOTIAZOLES SUSTITUIDOS COMO AGONISTAS DE ADENOSINA A1 Y A2b |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant, registration | ||
FD | Application declared void or lapsed |